bioRxiv preprint doi: https://doi.org/10.1101/2020.01.29.924555; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy Magali Humbert1,2,#, Kristina Seiler1,3, Severin Mosimann1, Vreni Rentsch1, Sharon L. McKenna2,4, Mario P. Tschan1,2,3 1Institute of Pathology, Division of Experimental Pathology, University of Bern, Bern, Switzerland 2TRANSAUTOPHAGY: European network for multidisciplinary research and translation of autophagy knowledge, COST Action CA15138 3Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland, 4Cancer Research, UCC, Western Gateway Building, University College Cork, Cork, Ireland. #Corresponding Author: Magali Humbert, Institute of Pathology, Division of Experimental Pathology, University of Bern, Murtenstrasse 31, CH-3008 Bern, Switzerland, E-mail:
[email protected], Tel: +41 31 632 8788 Running Title: FASN impairs TFEB activity in AML Key words: FASN/AML/ATRA/TFEB/mTOR/autophagy bioRxiv preprint doi: https://doi.org/10.1101/2020.01.29.924555; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Fatty acid synthase (FASN) is the only human lipogenic enzyme available for de novo fatty acid synthesis and is often highly expressed in cancer cells.